Cat. No. | Product name | CAS No. |
DC66858 |
Dacliximab
Featured
Daclizumab (Zenapax) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (Zenapax) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA. Daclizumab (Zenapax) can be used for multiple sclerosis research. |
152923-56-3 |
DC66859 |
Camidanlumab
Featured
Camidanlumab (HuMax-TAC) is a CD25 monoclonal antibody. Camidanlumab targets the cell-surface antigen CD25, which is over-expressed on a variety of hematological tumors and shows limited expression on normal tissues. Camidanlumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including lymphoma and leukemia. |
921618-45-3 |
DC66860 | Singapore ASTR patent anti-IL-2R beta / IL-2R gamma Featured | |
DC66861 |
Nemolizumab
Featured
Nemolizumab (CIM331) is a humanized antihuman interleukin-31 receptor A monoclonal antibody that inhibits the binding of interleukin-31 (IL-31) to its receptor and subsequent signal transduction. Nemolizumab can used be in research of atopic dermatitis (AD). |
1476039-58-3 |
DC66862 |
Itepekimab
Featured
Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD). |
2226742-52-3 |
DC66863 |
Tozorakimab
Featured
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease. |
2376858-66-9 |
DC66864 | Torudokimab Featured | |
DC66865 |
Etokimab
Featured
Etokimab (Antibody ANB 020) is a humanized monoclonal antibody that targets IL-33. Etokimab can be used for the research of atopic dermatitis. |
2022981-44-6 |
DC66866 |
Talacotuzumab
Featured
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models. |
1826831-79-1 |
DC66867 | SNG-CD123A Featured | |
DC66868 | MEDI2045 Featured | |
DC66869 |
Depemokimab
Featured
Depemokimab (GSK-3511294) is a long-acting anti-IL-15 monoclonal antibody. Depemokimab can be used for research of asthma. |
2243274-14-6 |
DC66870 | Abgenix anti-IL-5 Featured | |
DC66871 | 1-Propanone, 1-(3-chlorophenyl)-3-(methylthio)- Featured | 1341108-31-3 |
DC66872 | 4-Hepten-3-one, 1,7-bis(4-hydroxy-3-methoxyphenyl)- Featured | 79067-88-2 |
DC66873 | 4-Hepten-3-one, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (4Z)- Featured | 81569-02-0 |
DC66874 | WAY-311207-A Featured | 58575-74-9 |
DC66875 |
CDK1-IN-2
Featured
CDK1-IN-2 is a CDK1 inhibitor (IC50: 5.8 μM). |
220749-41-7 |
DC66876 | Rpn11-IN-1 Featured | |
DC66877 |
New Red
Featured
New Red is a color additive that can be used to dye flour as well as meat products. |
220658-76-4 |
DC66878 | 9-(dimethylamino)-3-(4-ethylphenyl)pyrido[1,2]thieno[3,4-d]pyrimidin-4-one Featured | 869802-44-8 |
DC66879 | ST-14328 Featured |